Related Experiment Video

Updated: Sep 5, 2025

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.1K

Correlation between CYP2C9 gene polymorphism and warfarin dose in Chinese Han population with coronary heart disease

Qiyu Zuo1, Li Li1, Mingjing Zhong1

  • 1Department of Cardiology, The People's Hospital of Huadu, Guangzhou, China. zuoqiyu0729@163.com.

Cellular and Molecular Biology (Noisy-Le-Grand, France)
|July 12, 2022
PubMed

Insights

CYP2C9 gene variations influence warfarin dosage in Chinese heart disease patients. Patients with the CYP2C9*1/*3 genotype require lower warfarin doses and have a higher risk of overdose.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Clinical Laboratory Science

Background:

  • Warfarin is a critical anticoagulant for coronary heart disease (CHD) patients.
  • Individualized warfarin dosing is essential due to its narrow therapeutic index.
  • CYP2C9 gene polymorphism is known to affect warfarin metabolism and efficacy.

Purpose of the Study:

  • To investigate the association between CYP2C9 gene polymorphism and warfarin dosage requirements in Chinese Han patients with CHD.
  • To evaluate the impact of CYP2C9 genotypes on the risk of anticoagulation overdose during initial warfarin therapy.

Main Methods:

  • A case-control study involving 200 CHD patients on warfarin and 200 healthy controls from the Chinese Han population.
  • Genotyping of CYP2C9 and analysis of allele frequencies.
  • Comparison of warfarin daily doses and international normalized ratio (INR) levels across different CYP2C9 genotypes.
  • Assessment of anticoagulation overdose incidence based on CYP2C9 genotype.

Main Results:

  • No significant differences in CYP2C9 genotype and allele frequencies were observed between the CHD patient group and the healthy control group.
  • Patients with the CYP2C9*1/*3 genotype required a significantly lower mean daily warfarin dose compared to those with the wild-type *1/*1 genotype.
  • The incidence of anticoagulation overdose was significantly higher in patients with the CYP2C9*1/*3 genotype compared to the *1/*1 genotype.

Conclusions:

  • CYP2C9 gene polymorphism is correlated with warfarin dose requirements in Chinese Han patients with CHD.
  • The CYP2C9*1/*3 genotype is associated with reduced warfarin metabolism, increased sensitivity, and a higher risk of overdose.
  • Genetic testing for CYP2C9 may aid in optimizing warfarin therapy and improving patient safety in this population.

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

838
High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

11.9K

Related Concept Videos

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
290
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.7K
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
14.1K
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
118
Time Course of Drug Effect01:14

Time Course of Drug Effect

The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.2K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
374